Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 3 | Arthritis Research & Therapy

Figure 3

From: NF-κB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor

Figure 3

Quantitative estimation of the suppressive effect of dehydroxymethylepoxyquinomicin on in vivo osteoclastogenesis. The mean number of tartrate-resistant acid phosphatase-positive giant cells with four or more nuclei in the individual ankle joints of arthritic mice treated with vehicle alone (n = 13), of mice treated with dehydroxymethylepoxyquinomicin (DHMEQ) (n = 12), and of normal mice (n = 6) were counted under a microscope by two investigators in a blinded manner to the assignment of mouse groups. The results shown are the mean ± standard error of the mean of four independent counts, and were compared by Student's t test.

Back to article page